Latest Off-label use Stories
Despite Federal Drug Administration regulation of the approval and use of pharmaceutical products, "off-label" marketing of drugs (for purposes other than those for which the drug was approved) has occurred in all aspects of the US health care system.
DoctorDirectory, a leading market services company serving healthcare professionals and pharmaceutical industry clients, surveyed practicing physicians in the US to assess physician attitudes on the FDA's Bad Ad Program. Asheville, NC (Vocus/PRWEB) March 04, 2011 In May, 2010 The US Food and Drug Administration launched a program designed to educate healthcare providers (HCPs) and enlist them in helping the agency spot misleading prescription drug information.
Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients â€” a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.
A new editorial article, published in the Canadian Medical Association Journal, suggests physicians should be more careful when prescribing drugs "off-label".
Top-selling drugs, known as atypical antipsychotic medications, lack evidence that theyâ€™ll actually be beneficial, according to a new study.
MUNICH, November 19, 2010 /PRNewswire/ -- Many of the medications used to treat children have been developed almost exclusively for adults and approved for them.
More than 17,000 healthcare providers, including doctors, have received money from several major drug companies to talk to other doctors about their products.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
SHORT HILLS, N.J., Sept. 17 /PRNewswire/ -- Fresh off his victory for a whistle-blower in the Forest Pharmaceuticals, Inc.
Allergan Inc, maker of the popular Botox anti-wrinkle treatment, said on Wednesday that it had agreed to pay $600 million to settle an investigation into whether the company had illegally marketed the drug for off-label uses.